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Comprehensive Review
A systematic review and meta-analysis of risk
factors for postherpetic neuralgia
Harriet J. Forbes*, Sara L. Thomas, Liam Smeeth, Tim Clayton, Ruth Farmer, Krishnan Bhaskaran,
Sine´ad M. Langan
Abstract
Patients with herpes zoster can develop persistent pain after rash healing, a complication known as postherpetic neuralgia. By
preventing zoster through vaccination, the risk of this common complication is reduced. We searched MEDLINE and Embase for
studies assessing risk factors for postherpetic neuralgia, with a view to informing vaccination policy. Nineteen prospective studies were
identified.Meta-analysis showed significant increases in the risk of postherpetic neuralgia with clinical features of acute zoster including
prodromal pain (summary rate ratio 2.29, 95% confidence interval: 1.42-3.69), severe acute pain (2.23, 1.71-2.92), severe rash (2.63,
1.89-3.66), and ophthalmic involvement (2.51, 1.29-4.86). Older age was significantly associated with postherpetic neuralgia; for
individual studies, relative risk estimates per 10-year increase ranged from 1.22 to 3.11. Evidence for differences by gender was
conflicting,with considerable between-study heterogeneity. A proportion of studies reported an increased risk of postherpetic neuralgia
with severe immunosuppression (studies, n5 3/5) and diabetesmellitus (n5 1/4). Systemic lupus erythematosus, recent trauma, and
personality disorder symptoms were associated with postherpetic neuralgia in single studies. No evidence of higher postherpetic
neuralgia risk was foundwith depression (n5 4) or cancer (n5 5). Our review confirms a number of clinical features of acute zoster are
risk factors for postherpetic neuralgia. It has also identified a range of possible vaccine-targetable risk factors for postherpetic neuralgia;
yet aside from age-associated risks, evidence regarding risk factors to inform zoster vaccination policy is currently limited.
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1. Introduction
Postherpetic neuralgia (PHN) is pain after an acute episode of
herpes zoster (commonly known as shingles) continuing beyond
rash healing.16 The pain has been described as a constant
burning or stabbing sensation, and some individuals experience
allodynia (pain triggered from light contact with nonpainful
stimuli).47 Symptoms can persist for months or even years, and
the condition can profoundly affect a patient’s quality of life.12,24
PHN is the most common complication of zoster; an estimated
12.5% of patients with zoster aged $50 years have PHN 3
months after zoster onset, and the proportion affected increases
sharply with age.
Postherpetic neuralgia is often refractory to treatment.10,20,40
Despite decades of research, evidence for the efficacy of
administering antivirals at first appearance of the rash in reducing
PHN incidence is unconvincing.7 However, an effective live-
attenuated vaccine is now available providing protection against
zoster and might be used to protect those most likely to develop
PHNand other complications of zoster.30,36 Apart from age, other
often reported risk factors for PHN relate largely to characteristics
of the acute zoster episode, particularly, the severity of acute pain
and rash at initial zoster presentation; however, the evidence has
not been systematically reviewed.14,31,32,42,48 Furthermore, as
these are not vaccine-targetable, there is interest in identifying
risk factors for PHN, which can be identified before the zoster
episode, to inform zoster vaccination policy.
This article aims to systematically collate and summarise the
epidemiological literature on risk factors for PHN including clinical
features of acute zoster and those which are “vaccine-
targetable.”
2. Methods
2.1. Study selection
2.1.1. Search terms
We searched all published journal articles in MEDLINE and
Embase between 1950 and February 3, 2014. We searched for
articles containing PHN terms and risk factor analysis terms
(Box 1 for full details). The search strategy used both subject
heading and text word searches. Initial search terms were
updated after searching the reference lists of relevant articles.
To capture relevant grey literature, the New York Academy of
Medicine Grey Literature Report (www.greylit.org), the Elec-
tronic Theses Online Service through the British Library (http://
ethos.bl.uk), and the ISI Conference Proceedings Citation Index
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(http://isknowledge.com) were searched for the terms: “PHN”
or “postherpetic neuralgia” or “postherpetic neuralgia,” within
the keywords or title (Box 1).
Box 1
Search terms used.
Medline:
[ { (“Postherpetic neuralgia”[exploded MeSH] OR PHN[Title or abstract] OR
“postherpetic neuralgia”[Title or abstract] OR “post herpetic neuralgia”[Title or
abstract] OR post-herpetic neuralgia[Title or abstract] OR “postherpetic
pain”[Title or abstract] OR “post herpetic pain”[Title or abstract] OR post-
herpetic pain [Title or abstract] OR ((“Neuralgia”[exploded MeSH] OR
“Pain”[exploded MeSH] OR neuralgia [Title or abstract] OR pain [Title or
abstract]) AND (“Herpes zoster”[exploded MeSH] OR zoster[Title or abstract]
OR shingles[Title or abstract] OR zona[Title or abstract] OR VZV[Title or
abstract]))
AND (“Risk factors”[exploded MeSH] OR “Epidemiologic studies”[exploded
MeSH] OR “Odds ratio”[exploded MeSH] OR “Multivariate analysis”[exploded
MeSH] OR “Logistic Models”[exploded MeSH] OR “Prevalence”[exploded
MeSH] OR “Incidence”[exploded MeSH] OR “odds ratio”[Title or abstract] OR
“risk ratio”[Title or abstract] OR “relative risk”[Title or abstract] OR “risk
factor”[Title or abstract] OR risk[Title or abstract] OR predict*[Title or abstract]
OR correlat*[Title or abstract] OR etiol*[Title or abstract] OR aetiol*[Title or
abstract] OR prevalence[Title or abstract] OR incidence[Title or abstract] OR
rate*[Title or abstract]) }
OR “Postherpetic neuralgia/etiology”[exploded MeSH]
OR ((“Neuralgia/etiology”[MeSH] OR “Pain/etiology”[MeSH]) AND (herpes
zoster[exploded MeSH] OR “zoster”[Title or abstract] OR “shingles”[Title or
abstract] OR “zona”[Title or abstract] OR “VZV”[Title or abstract])) ]
AND “Humans”[MeSH]; limited to articles in language: ENGLISH
Embase:
[ { (“Postherpetic neuralgia”[exploded subject heading] OR “PHN”[Title or
abstract] OR “postherpetic neuralgia”[Title or abstract] OR “post herpetic
neuralgia”[Title or abstract] OR “post-herpetic neuralgia”[Title or abstract] OR
“postherpetic pain”[Title or abstract] OR “post herpetic pain”[Title or abstract]
OR post-herpetic pain [Title or abstract] OR ((“Neuralgia”[exploded subject
heading] OR “Pain”[exploded subject heading] OR “neuralgia” [Title or
abstract] OR “pain” [Title or abstract]) AND (herpes zoster[exploded subject
heading] OR “zoster”[Title or abstract] OR “shingles”[Title or abstract] OR
“zona”[Title or abstract] OR “VZV”[Title or abstract]))
AND (“Risk factor”[exploded subject heading] OR “Epidemiology”[exploded
subject heading] OR “Odds ratio”[exploded subject heading] OR “Multivariate
analysis”[exploded subject heading] OR “Statistical model”[exploded subject
heading] OR “Prevalence”[exploded subject heading] OR “Incidence”[ex-
ploded subject heading] OR “odds ratio” OR “risk ratio” OR “relative risk” OR
“risk factor” OR “risk” [Title or abstract] OR “risk factor”[Title or abstract] OR
“predict*”[Title or abstract] OR “correlat*”[Title or abstract] OR “etiol*”[Title or
abstract] OR “aetiol*”[Title or abstract] OR “prevalence”[Title or abstract] OR
“incidence”[Title or abstract] OR “rate*”[Title or abstract]) }
OR “Postherpetic neuralgia/etiology”[exploded subject heading]
OR ((“Neuralgia/etiology”[subject heading] OR “Pain/etiology”[subject head-
ing]) OR (herpes zoster[exploded subject heading] OR “zoster”[Title or
abstract] OR “shingles”[Title or abstract] OR “zona”[Title or abstract] OR
“VZV”[Title or abstract])) ]
AND “Humans”[subject heading]; limited to language: ENGLISH
Grey literature:
New York Academy of Medicine Grey Literature Report: PHNOR postherpetic
neuralgia OR title:(postherpetic AND neuralgia) OR title:PHN
ISI Conference Proceedings Citation Index: [ {TS5(PHN or “postherpetic
neuralgia” or “post herpetic neuralgia”) AND TS5(risk or epidem* or “odds
ratio” or rate)} OR {TI5(PHN or “postherpetic neuralgia” or “post herpetic
neuralgia”)}] AND TI5(risk or epidem* or “odds ratio” or rate) AND LANGUAGE:
(English).
Note: In both databases the subject heading terms are arranged in a hierarchy
with more specific linked subheadings arranged beneath wider terms. Exploding
a subject heading indicates that the search includes all results below that
heading.
2.2. Inclusion and exclusion criteria
Criteria were developed in an iterative process after preliminary
searches. We included studies based on original data from
analytical epidemiological studies, among adults (18 years1) with
zoster. Postherpetic neuralgia had to be a study outcome and an
age-adjusted effect estimate was required. We included risk
factors, which were either (1) clinical features of the acute zoster
episode or (2) vaccine-targetable, defined as risk factors identifi-
able before the onset of the zoster rash. Studies assessing only
age as a risk factor were required to treat age as a continuous
exposure (ie, linear on a log scale) such that its effects on PHN risk
could be reported per 10-year increase. Studies assessing genes
as risk factors for PHNwere not required to have an age-adjusted
effect measure, because allele frequencies are not typically
associated with age.
We omitted studies assessing antiviral therapy as a de-
terminant of PHN as they have been recently summarised in
a Cochrane Systematic Review7; we also omitted studies
assessing other PHN treatments (such as acupuncture and
corticosteroids). We excluded studies examining risk factors for
PHN within a general population sample (where patients with
PHN were compared with non-zoster controls) because the risk
of PHN in the general population comprises 2 parts; first, the risk
of zoster and second, the risk of developing PHN among those
with zoster. In these studies, it is impossible to disentangle
whether any identified risk factors are simply predictive of zoster
itself, or whether they are specifically risk factors for getting
PHN. We also excluded studies restricted to specific clinical
subgroups of patients with zoster, such as individuals with HIV,
because their risk factors for PHN may differ. We restricted to
English articles only; however, we did not place any restriction
on study location or publication status.
2.3. Selecting studies
The titles and abstracts of all identified articles were assessed. If
a study was deemed to potentially fulfil the inclusion criteria, full-
text versions were retrieved and assessed. Reference lists of all
retrieved articles were searched. To assess how reliably the study
eligibility criteria were applied, a second author (R.F.) applied the
inclusion criteria to a random 10% sample of all articles, and
agreement between the primary allocation and the sample
allocation was tested using Cohen’s kappa statistic.29 A kappa
score of 1 denotes full agreement, and kappa values greater than
0.75 indicate excellent agreement.44
2.4. Data extraction
Extraction tables were piloted by S. L. Thomas and H. J.
Forbes and then applied to remaining studies. Data (listed in
Appendix, available online as Supplemental Digital Content at
http://links.lww.com/PAIN/A132) were extracted by H. J.
Forbes for each study. Authors were contacted for missing
information (see appendix for template e-mail to correspond-
ing authors, available online as Supplemental Digital Content
at http://links.lww.com/PAIN/A132). When individual studies
used multiple definitions of PHN, results classifying PHN as
pain at 3 months after zoster onset (or that closest to 3
months) were extracted for the main analysis, as this is the
most widely used definition of PHN.12,17,30,36,45 Results from
other PHN definitions were extracted for the Appendix
(available online as Supplemental Digital Content at
http://links.lww.com/PAIN/A132).
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2.5. Assessing risk of bias
The risk of bias assessment was based on the Cochrane
Collaboration approach, in which each study is assessed
separately for prespecified bias domains (see Appendix for
further details available online as Supplemental Digital Content at
http://links.lww.com/PAIN/A132).
We also considered the validity of each study based on the
sampling of patients with zoster, numbers declining to participate,
and their characteristics, particularly the percentage develop-
ing PHN.
2.6. Data analysis
When at least 2 studies were deemed to be capturing the same
risk factor within similar populations, we assessed between-
study heterogeneity using the Cochrane Q statistic and the I2
statistic, with I2 . 50% used as a threshold indicating moderate
heterogeneity. In the absence of heterogeneity, we planned to
combine the estimates and produce a summary relative risk using
fixed effects meta-analysis. However, for some risk factors, there
was significant between-study statistical heterogeneity; there-
fore, we performed posthoc analysis to help ascertain the
possible reasons for heterogeneity. This included rerunning the
meta-analysis removing studies at high risk of bias and
comparing I2 values between clinical and methodological
subgroups to evaluate potential sources of heterogeneity.22 For
this latter analysis, summary estimates from subgroups were
formally compared using meta-regression; we compared sub-
groups according to (1) mean age of the study population ($60
years vs ,60 years), (2) definition of PHN (pain at 4 months vs
pain at 3 months), (3) ascertainment of PHN (self-reported vs
ascertained from medical records), (4) whether immunosuppres-
sive patients were included or excluded, and (5) sources of study
population (primary care vs other).
We also created a funnel plot to determine the risk of
publication bias; gender was the only risk factor assessed in
sufficient studies to be suitable for assessment (age effects were
reported in different units making it unsuitable). The odds ratios
(OR), representing the effect estimate of gender on PHN, were
plotted against the standard error of the log odds,41 representing
the precision of the estimate, and symmetry was assessed
visually (as there were too few studies to perform a formal test).43
Statistical analyses were performed in STATA (version 13.1).
3. Results
The initial search identified 3614 articles. After removing
duplicates, 2559 titles and abstracts were screened. Of these,
116 full-text articles were retrieved, 19 of which were included in
the review (Fig. 1). Excluded studies are listed in the Appendix
(Table A1), available online as Supplemental Digital Content at
http://links.lww.com/PAIN/A132.
Agreement between reviewers over the application of the
inclusion criteria was very good (kappa score, 0.88). From the
10% sample of articles double screened, 1 study was not agreed
on; the second reviewer initially selected this study11 for inclusion;
however, both reviewers subsequently agreed this extra article
replicated a study already selected.13
3.1. Study characteristics and findings
Study characteristics are described in Table 1. There were 18
cohort studies and 1 case-base study (a modified case–control
study, where the risk ratio is estimated by sampling controls from
those at risk at the start of follow-up).39 Study sizes ranged from
55 to 34,280, and 17/19 studies had less than 1000 participants
at baseline. Zoster diagnoses were predominantly based on
clinical opinion. Definitions of PHN were presence of pain 3
months after rash onset in 10 studies, although other definitions
from 1 to 6 months were used. The percentage of patients with
zoster developing PHN ranged from 2.6% to 67.3%. Mean age of
study participants (available in 9 studies) ranged from52.3 to 67.7
years. Studies were all from high-income countries.
Study findings are summarised in Table 2 and Figures 2 and 3.
Data were collected on clinical features of the acute episode
including pain (15), rash extent and location (14), rash duration (9),
sensory dysfunction (3), and other clinical features (11), and also
vaccine-targetable risk factors including age and gender (18
studies), severe immunosuppression (5), other physical comorbid-
ities such as autoimmune conditions (4), diabetes (6), cancer (5),
recent physical trauma (1), psychological comorbidities (4), and
other risk factors (9).
3.2. Clinical features of acute zoster episode as risk factors
3.2.1. Pain
3.2.1.1. Prodrome
Eleven cohort studies and the case-base study collected data on
prodromal pain, ie, pain appearingbefore rashonset. Seven included
prodromal pain in the final age-adjustedmodel and 5 reported effect
estimates, with each giving a point estimate above 1. We obtained
apooled effect estimate of 2.29, 95%confidence interval (CI): 1.42 to
3.69 (Pheterogeneity50.716; I
250.0%) in fixed effectmeta-analysis. A
cohort study among 533 immunocompetent patients reported
a shorter prodrome (#3days) before rash onsetwas associatedwith
reduced risk of PHN (adjOR: 0.49, 95% CI: 0.24-0.99).
3.2.1.2. Severe acute pain during zoster
Twelve cohort studies investigated severe acute pain as a risk
factor for PHN. Although definitions of severe acute pain varied
among studies, eg, pain scoring $4 using the Neuropathic Pain
Questionnaire5 and pain scoring $5 on the Visual Analogue
Scale,9 8 reported it as a binary variable enabling us to pool
estimates; there was good evidence that severe acute pain was
associated with increased risk of PHN (rate ratio [RR]: 2.23,
95% CI: 1.71-2.92, Pheterogeneity 5 0.649; I
2 5 0.0%).
3.2.1.3. Allodynia
Allodynia was investigated in 3 cohort studies. One study
reported a greater than 4-fold increased risk of PHN with brush
(adjOR: 5.89, 95% CI: 1.50-23.1) and stretch-evoked allodynia
(adjOR: 4.13, 95% CI: 0.98-17.50)19; however, small numbers
(N5 93) led to wide CIs. A study among hospital patients treated
in a pain clinic found no effect of allodynia (definition unclear;
adjOR: 0.82, 95% CI: 0.24-2.81), whereas a final cohort study
similarly reported no evidence of effect.5,26 A summary estimate
was not calculated because of the varying definitions of allodynia.
3.2.1.4. Pain interferes with daily functioning
Pain interfering with daily functioning at zoster onset was assessed
in 3 cohort studies. The first, among 1358 individuals, reported
a 1-unit increase in zoster brief pain inventory interference score
was associated with 18% increase in PHN risk (adjOR: 1.18, 95%
CI: 1.05-1.31).13 Two other cohort studies reported binary (yes or
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no) data on pain interference. One found over 2-fold increased
risk,27 whereas the other found no evidence of association; the
summary estimate of these 2 studies suggested there was strong
evidence that pain interfering with daily functioning was associated
with PHN (summary RR: 2.10, 95% CI: 1.27-3.48).
3.2.2. Rash severity and location
3.2.2.1. Severe rash
Rash severity data were collected in 8 studies. Five included it in
their final age-adjusted model (although one did not report an
OR); when combined in meta-analysis, severe rash was strongly
associatedwith PHN risk (summary RR: 2.63, 95%CI: 1.89-3.66,
Pheterogeneity 5 0.892; I
2 5 0.0%).
3.2.2.2. Ophthalmic involvement
A total of 13 studies recorded information on zoster location. Only
3 studies reported an effect estimate for ophthalmic involvement.
Each of these 3 studies reported a point estimate above 1, yet the
CIs crossed 1. When combining in a meta-analysis, there was
evidence that ophthalmic zoster was associated with over twice
the risk of PHN, compared with nonophthalmic zoster (summary
RR: 2.51, 95% CI: 1.29-4.86, Pheterogeneity 5 0.782; I
2 5 0.0%).
3.2.3. Rash duration at presentation
Longer rash duration at presentation of zoster showed some
evidence of being associated with reduced risk of PHN. A study
on 598 immunocompetent patients showed for everyday the rash
was present since presentation in primary care; there was over
20% reduced risk of PHN (adjOR: 0.78, 95% CI: 0.64-0.97).35
Three other cohort studies estimated the risk of PHN for everyday
from onset to diagnosis; point estimates were all below 1 (yet CIs
were wide).9,25,27 The summary estimate from meta-analysis
showed a small reduction in PHN risk with everyday since rash
onset (0.93, 95% CI: 0.86-0.99).
3.2.4. Other
One study assessed pinprick hypaesthesia (or numbness) as
a risk factor for PHN: it was associatedwith a 7-fold increased risk
of PHN (adjOR: 7.72, 95% CI: 2.00-29.90).
3.3. Vaccine-targetable risk factors
3.3.1. Age
Eighteen studies assessing the effects of age showed an
increased risk of PHN with greater age. When possible, we
summarised the effect of a 10-year increase in age on PHN risk
(n 5 9). The point estimates ranged from 1.22 to 3.11 per 10
years; the meta-analysis showed strong evidence of between-
study heterogeneity (Pheterogeneity 5 0.029; I
2 5 55.1%). A small
study (N5 249) showing an increased risk of PHN with a 10-year
increase in age (adjRR: 1.22, 95% CI: 1.00-1.48) was excluded
from themeta-analysis as the effect was reported as a risk ratio. In
posthoc analysis, there was some weak evidence that the effect
of age was associated with age of the study population (P value
from meta-regression 5 0.08; specifically the effect of age on
PHN risk seemed higher in studies where the mean age was$60
Figure 1. Flow diagram describing study selection.
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Table 1
Studies assessing vaccine-targetable risk factors for postherpetic neuralgia nested within a population of patients with zoster: study characteristics.
Cohort studies
First author
publication
year
Country, year
of study
Study population Study size Mean (SD)
age in years
at baseline
Outcome Patients with
PHN, n (%)
Definition and
method of
identifying
zoster
Definition and
method of
ascertaining
PHN
Method of
ascertaining risk
factor(s)
Risk factors assessed Statistical
analysis
Asada
et al.2
Japan, 2008-
2010
Patients with acute
zoster registered in
a cohort study on VZV
immunity; aged $50 y
258 recruited
247 analysed
11 lost to follow-up
Not reported PHN at 3 mo after
zoster
32 (13.0) Notified during
telephone follow-
up and confirmed
through
evaluation of
clinical symptoms
by 3
dermatologists
and PCR
Pain 3 mo after
rash onset
Telephone survey
to ascertain pain
status by
secretariat
members.
Survey forms and
examination by
dermatologists
Age, gender, history of
zoster, state of VZV-
specific cell-mediated
immunity (using VZV skin
test reaction: no oedema
formation and ,5 mm
diameter of red skin
indicated weaker VZV-
specific cell-mediated
immunity)
Logistic
regression
Bouhassira
et al.5
France, 2007-
2008
Patients presenting to
General Practitioners
(GPs) years with acute
zoster; aged $50 y
1358 recruited
1091 analysed
267 lost to
follow-up
67.7 (10.7) PHN at 3 mo after
zoster
127 (11.6) Physician
diagnosis within 7
d of rash onset,
no history of
zoster within
previous 12 mo
Pain 3 mo after
rash onset
Telephone
interview, using
question, “Do you
still have pain
associated with
your shingles?”
Physician interview and
patient completed
questionnaire at zoster
diagnosis
Age, gender, family
situation, living
arrangements, delay in
diagnosis, associated
disease (undefined),
average pain intensity,
pressure allodynia, brush-
evoked allodynia, global
DN4 score, NPSI score,
ZBPI interference score,
SF-12 physical and
mental component score,
HADS score, and
analgesic treatment
Logistic
regression
Cebria´n-
Cuenca
et al.6
Spain, 2006-
07
Convenience sample of
patients with acute
zoster from 25 general
practitioners; aged
.14 y
146 recruited
124 analysed
22 lost to follow-up
16 declined to
participate
Median 63.5
(range:
19-94)*
PHN at 3 mo after
zoster
18 (14.5) Physician
diagnosis of
zoster
Pain 3 mo after
rash onset.
Telephone/home
interview by study
investigators
Interview with patients
and review of medical
records
Age, gender, prodromal
pain, extremities
localization, sacrum
localization, time between
symptom onset and
clinical diagnosis, time
between rash onset and
clinical diagnosis, antiviral
use
Logistic
regression
Coen et al.9 England,
1998-2001
Patients presenting to
primary care with acute
zoster; any age
280 recruited
272 analysed
8 lost to follow-up
Not reported
(range 0-99)
PHN at 3 mo after
zoster
52/250 (20.8) Physician
diagnosis within 7
d of rash, referred
to 2 investigators
for clinical and
PCR or IFA
confirmation
VAS score $3.3
mo after rash
onset
Follow-up visit or
telephone
interview with
research nurse
Physician interview at
enrolment
Age, gender, prodromal
pain, extent of rash, time
from onset of rash,
ophthalmic branch
involvement, pain severity
using VAS
Logistic
regression
(continued on next page)
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Table 1 (continued)
Cohort studies
First author
publication
year
Country, year
of study
Study population Study size Mean (SD)
age in years
at baseline
Outcome Patients with
PHN, n (%)
Definition and
method of
identifying
zoster
Definition and
method of
ascertaining
PHN
Method of
ascertaining risk
factor(s)
Risk factors assessed Statistical
analysis
Drolet
et al.12
Canada, 2005-
2006
Immunocompetent
patients presenting to
general practice or
specialist centres, with
zoster; aged $50 y
249 recruited
all analysed
65.6 (10.8) PHN at 3 mo after
zoster
56 (22.5) Physician
diagnosis within
14 d of rash
onset. Physicians
received training
on zoster
diagnosis and
their first 3
patients were
confirmed by PCR
Severe pain 3 mo
after rash onset
Patient
completed pain
questionnaire at
patients home
Physician interview and
patient completed
questionnaire at zoster
diagnosis
Age, gender, education,
working, income, has
other pain condition, EQ-
5D health status score
before and during zoster
in 5 domains: mobility,
self-care, usual activities,
having pain/discomfort,
being anxious/depressed
(rated none, some, or
severe problems), VAS
score before and during
zoster, delay between
recruitment and rash
onset, dermatome
affected, number of
lesions, worst pain,
prodrome, duration of
prodrome, worse
prodromal pain, reported
pain interference score,
antiviral treatment and
timing of antiviral
treatment, other
medications. Immune
suppressed patients
(using high-dose oral
corticosteroids or other
immunosuppressive
drugs, having invasive
cancer or HIV/AIDS)
included in sensitivity
analysis
Log-
binomial
regression
(continued on next page)
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Table 1 (continued)
Cohort studies
First author
publication
year
Country, year
of study
Study population Study size Mean (SD)
age in years
at baseline
Outcome Patients with
PHN, n (%)
Definition and
method of
identifying
zoster
Definition and
method of
ascertaining
PHN
Method of
ascertaining risk
factor(s)
Risk factors assessed Statistical
analysis
Haanpaa,
200019
Finland, year
not given
Primary care zoster
patients without
immunosuppression,
psychiatric illness,
substance abuse,
systemic, or metabolic
disease, neurologic
disease influencing
somatosensory testing;
any age
113 recruited
93 analysed
58 (17.2) PHN at 3 mo after
zoster
28 (25) Physician
diagnosis
Pain 3 mo after
rash onset
Follow-up visit, or
if nonattendance
telephone
interview or mail,
by study
investigator
Interview with patients 1-
10 d after rash onset by
study investigators
Age, gender, severity of
zoster rash (mild: covers
,quarter of affected
dermatome, severe:
covers .3 quarters of
affected dermatome,
moderate: in between
above), localisation of
rash, prodromal pain,
acute pain (none, mild,
moderate, severe),
antiviral use, analgesic
use, allodynia (brush,
stretch, and compression
evoked), and pin-prick
hypaesthesia
Logistic
regression
Helgason
et al.21
Iceland, 1990-
1995
Patients presenting to
participating GPs with
first ever zoster
diagnosis, without
cognitive impairment;
any age
421 recruited
391 analysed
30 lost to follow-up
Not available PHN at 3 mo after
zoster
28 (7.2) Physician
diagnosis and
further
confirmation by
study
investigators
using clinical
information from
GPs and patients
Pain 3 mo after
rash onset
Telephone
interview/home
visit by principal
investigator
Researcher interview,
supplemented by data
from GP practice records
Age and gender Logistic
regression
Jih, 200923 Taiwan, 2000-
2006
Patients with zoster in
nationally
representative 1 million
claims data sample,
with primary care and
inpatient data linked;
any age
34,280 Not reported
(1-.80)
PHN at 3 mo after
zoster
Exact number
not given (8.6)
ICD-9 codes for
zoster in inpatient
or outpatient
service claim
Pain .90 d after
rash onset
ICD-9 zoster code
and neuralgia
treatment .90
d after first onset
ICD-9 codes: timing of
records with respect to
zoster or PHN is unclear
Age, gender, diabetes,
systemic lupus
erythematosus, HIV/AIDs,
breast cancer, liver
cancer, and lymphoma/
leukaemia
Poisson
regression
Jung
et al.25
Europe, US,
Canada,
Australia,
1990-1991
Patients with
immunocompetent
zoster recruited into 2
clinical trials; aged
$15 y
965 recruited
855 analysed
110 lost to
follow-up
52.3 (range
15-93)*
PHN at 4 mo after
zoster
114 (13.3) Physician
diagnosis of
zoster within 72 h
of rash onset
Pain 4 mo after
rash onset
Patient reported
at follow-up visit
Physician interview at
zoster diagnosis
Age, gender, rash
severity, rash duration,
prodrome, pain severity,
primary involvement of
the trigeminal
dermatome, number of
affected dermatomes,
presence of affected
nonadjacent
dermatomes, clinical trial
sample
Logistic
regression
(continued on next page)
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Table 1 (continued)
Cohort studies
First author
publication
year
Country, year
of study
Study population Study size Mean (SD)
age in years
at baseline
Outcome Patients with
PHN, n (%)
Definition and
method of
identifying
zoster
Definition and
method of
ascertaining
PHN
Method of
ascertaining risk
factor(s)
Risk factors assessed Statistical
analysis
Kanbayashi
et al.26
Japan, 2008-
2010
Patients treated at
a hospital pain clinic,
with zoster (unclear if
acute/persistent); age
unspecified
73 recruited
all analysed
Median 69
(range 27-90)
Ordered
categorical: no
PHN, PHN 3-6
mo, PHN 6 mo1
PHN 3-6 mo:
13 (18)
PHN 6 mo1:
25 (34)
Unclear Pain 3-6 or 6
mo1 after rash
onset
Medical records
of pain (unclear
how pain defined)
Extraction of variables
from clinical records at
initial visit
Age, gender,
comorbidities
(hypertension, angina,
diabetes, malignant
tumour, autoimmune
diseases) sleep disorder,
rash location, period of
onset, type and extent of
pain, VAS, prodrome,
allodynia
Ordered
logistic
regression
Katz et al.27 United States,
mid 1990s
Patients presenting to
hospital and community
physicians with acute
zoster; aged $18 y
129 recruited
102 analysed
8 lost to follow-up
19 excluded (initial
assessment
.30 d after
rash onset)
Patients with
PHN: 63.2
(15.1)
Patients
without PHN
59.2 (14.5)
PHN at 4 mo after
zoster
20 (19.6) Physician
diagnosis with no
more than 1
previous episode
of zoster, 15 y
ago
Pain;4 mo after
rash onset
Telephone
interview by
research
assistant or
psychologist
Psychologist
administered interview
within 30 d of rash onset
Age, gender, race,
education, marital status,
physical health, immune
compromise (definition
unclear, yet includes HIV,
currently treated for
cancer and high-dose
corticosteroids), presence
of a prodrome, zoster
location, zoster duration
acute pain intensity,
premorbid physical, role,
and social functioning (1
wk before and after rash
onset), symptoms of
depression and anxiety,
emotional well-being,
personality disorder
symptoms, health locus of
control, disease
conviction,
hypochondriasis,
somatosensory
amplification, somatic
symptoms, current major
depression or dysthymia
Logistic
regression
(continued on next page)
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Table 1 (continued)
Cohort studies
First author
publication
year
Country, year
of study
Study population Study size Mean (SD)
age in years
at baseline
Outcome Patients with
PHN, n (%)
Definition and
method of
identifying
zoster
Definition and
method of
ascertaining
PHN
Method of
ascertaining risk
factor(s)
Risk factors assessed Statistical
analysis
Kotani
et al.28
Japan, year not
given
Patients presenting to
hospitals with acute
zoster, excluding
patients recently on
immunosuppressive
therapy, or with serious
neurologic disorders;
aged $50
170 recruited
all analysed
65 (9) PHN at 2 mo after
zoster
52 (30.4) Physician
diagnosis of
painful
nontrigeminal
zoster (exc.
disseminated)
within 4 d of rash
onset, and
serological
confirmation
Any pain 6 mo
after rash onset
Assessed 24 h
after coming off
analgesics,
unclear how pain
was ascertained
Measured at zoster
diagnosis: method of
ascertainment unclear
Age, gender, comorbid
conditions (diabetes,
malignancy, immune
disorders, autoimmune
disease), prodromal pain,
localization, severity of
zoster rash, number of
skin lesions, degree of
acute pain, cerebrospinal
fluid interleukin 8
concentrations during and
at healing of herpetic rash
Logistic
regression
Opstelten
et al.33
Netherlands,
1994-1999
Patients with zoster
identified from EHRs
from primary care; any
age
837 identified
all analysed
Not available PHN at 3 mo after
zoster
22 (2.6) Medical code or
zoster mentioned
in the free text:
confirmed after
review of full
medical records
Pain at 3 mo after
rash onset
Any evidence of
pain in EHR; pain
record/analgesic
prescription
From previously recorded
medical records at zoster
diagnosis
Age, gender, localization,
comorbidity (diabetes,
chronic obstructive
pulmonary disease,
rheumatoid arthritis,
systemic lupus
erythematosus,
psychological problem at
zoster diagnosis),
medication at zoster
diagnosis (corticosteroids
within previous 14 d and
psycho-pharmaceuticals
within previous 3 mo),
painful prodrome,
consultation frequency,
chronic analgesics use
Logistic
regression
Opstelten35 Netherlands,
2001-2004
Immunocompetent
patients presenting to
GPs with acute zoster
and recruited into
a trial; aged .50 y
598 recruited
all analysed
651 not included:
470 refused
consent, 98
physician
declined to
participate, 83
unknown†
66.2 (9.8) PHN at 3 mo after
zoster
46 (7.7) Physician
diagnosis within 7
d of rash onset,
dermatome below
C6
Pain$30 on VAS
scale 3 mo after
study inclusion.
Patient filled in
postal survey
Measured at
baseline—questionnaire
and data from GP
Age, gender, rash
duration (in d) and
severity, prodromal pain,
pain severity, use of
antivirals, VZV antibodies
(IgM, IgA, IgG), VZV
viremia, and seven
psychological predictors:
negative self-efficacy,
pain catastrophizing,
positive expectation,
resignation, and trust in
health care, anxiety state
and anxiety disposition
Logistic
regression
(continued on next page)
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Table 1 (continued)
Cohort studies
First author
publication
year
Country, year
of study
Study population Study size Mean (SD)
age in years
at baseline
Outcome Patients with
PHN, n (%)
Definition and
method of
identifying
zoster
Definition and
method of
ascertaining
PHN
Method of
ascertaining risk
factor(s)
Risk factors assessed Statistical
analysis
Park et al.37 South Korea,
2008-2010
Patients presenting to
hospital with acute
zoster; any age
55 recruited
all analysed
PHN patients:
63.3 (15.9)
Non-PHN:
48.2 (16.8)
PHN at 1 mo after
zoster
15 (27.3) Physician
diagnosis within 7
d of rash onset
Pain persisting or
appearing 30
d after rash onset
Method unclear
Collected at
baseline—method
unclear
Age, sex, affected area,
pain intensity, and interval
between onset of rash and
hospital visit. Also,
maximal temperature
difference between
lesional and contralateral
normal skin, and size of
body surface area
showing thermal
asymmetry
Logistic
regression
Parruti
et al.38
Italy, 2006-
2008
Consecutive patients
presenting to primary
care or hospital with
acute zoster; age
unspecified
469 recruited
441 analysed
28 lost to follow-up
58.1 (20.4) PHN 1-3 mo after
zoster
130 (29.5) Physician
diagnosis any
time after rash
onset, with
laboratory
investigation of
uncertain cases
Any pain between
1-3 mo after
enrolment
Recorded at
follow-up visit or
by telephone
Patient completed
electronic forms at
enrolment
Age, gender, familial
status, educational level,
hypertension, diabetes,
HCV and/or HIV infection,
alcohol abuse smoking
status, familial history of
major cardiovascular
events, malignancies,
neurological diseases,
major depression,
psychiatric illness, allergy,
trauma at site of lesion (in
6 mo pre-enrolment),
surgical intervention at
site of lesions, zoster
dermatomeric district,
pain intensity at
presentation, rash
severity, prescribed
NSAIDs, antiviral use
Logistic
regression
Volpi et al.46 Italy, 2001-
2002
Patients with
immunocompetent
zoster presenting to
private dermatologists,
aged $18 y
533 recruited
219 analysed
Median age:
58 (18-82)
PHN 6 mo after
zoster
70 (32) Physician
diagnosis
Pain 6 mo after
rash onset, with
pain rating 3 or
higher (on scale
from 0 [no pain]
to 10)
Physician
diagnosis using
patient reported
pain at follow-up
Physician interview and
patient completed
questionnaire at zoster
diagnosis
At baseline: age, gender,
years of education,
presence and duration of
prodromal pain, intensity
of pain, localization of
rash, extent of rash,
abnormal sensations
(itch, tingle, allodynia),
systemic antiviral therapy
Logistic
regression
(continued on next page)
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Table 1 (continued)
Cohort studies
First author
publication
year
Country, year
of study
Study population Study size Mean (SD)
age in years
at baseline
Outcome Patients with
PHN, n (%)
Definition and
method of
identifying
zoster
Definition and
method of
ascertaining
PHN
Method of
ascertaining risk
factor(s)
Risk factors assessed Statistical
analysis
Woznaik
et al.50
United
Kingdom,
1998-2001
Patients presenting to
primary care with acute
zoster; any age
280 recruited
104 analysed
reasons for
noninclusion not
available
59 (range:
19-91)
PHN at 4 mo after
zoster
70 (67.3) Physician
diagnosis plus
confirmation by
PCR for VZV
Pain/abnormal
symptoms
$120 d
Follow-up visit or
phone interview
with study nurse
DNA preparation and
APOE genotyping
APOE genotypes ORs and
95% CI
generated
Prospective case-
base studies (where
the controls are
a sample of the base
population)
First author
publication year
Country
year of
study
Base population Cases and controls Study size Mean age
in years
(SD)
Definition and
method of
identifying zoster
Definition and
method of
ascertaining PHN
Method of
ascertaining risk
factor(s)
Risk factors assessed Statistical
analysis
Choo et al.8 United
States,
1990-
1992
Acute zoster patients
in HMO’s EHRs, with
continuous
membership at least
180 d before and at
least 90 d after zoster;
age unspecified
Cases: patients
developing PHN
37 cases Cases:
67.6 (14.5)
ICD-9 code for
incident zoster (no
zoster record before 6
mo). Medical records
of all patients with
a code screened by 2
reviewers
Symptoms in zoster
area .60 d from rash
onset
Screening of
previously recorded
medical records at the
time of zoster
diagnosis
Age, gender, health care
utilization, location of
zoster, prodromal
symptoms, time to crusting
of rash, interference of
zoster with daily living,
comorbidities recorded
180 d before zoster
(diabetes, cancer,
connective tissue disease,
HIV, organ transplant),
complications
(superinfection, motor
neuropathy, keratitis,
uveitis, oticus, transient
ischaemic attack, from
vasculitis) cytotoxic
chemotherapy 180
d before zoster, antiviral
treatment, corticosteroids
180 d before and 30
d after zoster
Logistic regression
with a correction
(continued on next page)
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years) (Appendix Table A2, available online as Supplemental
Digital Content at http://links.lww.com/PAIN/A132). There was
no evidence that the effect of age on PHN risk varied by definition
of PHN (P 5 0.52), ascertainment of PHN (P 5 0.14),
immunosuppression status (P 5 0.23), or sources of study
population (P 5 0.18).
3.3.2. Gender
Of 9 studies reporting the age-adjusted association between
gender andPHN, somesuggested an increased riskof PHNamong
females,9,25,38 others a decreased risk,2,5 whereas others found no
evidence of an association.2,6,8,23,33,37 These conflicting results
were supported by strong evidence of between-study heteroge-
neity (Pheterogeneity , 0.001; I
2 5 73.9%). In posthoc analysis, the
effect of female gender seemed protective in studies in which the
mean age was $60 years, compared with among studies with
mean age,60 years, for which female gender increased the risk of
PHN; heterogeneity was reduced within these subgroups (,1% in
both) (Appendix Table A2, available online as Supplemental Digital
Content at http://links.lww.com/PAIN/A132). There was no ev-
idence that the effect of gender on PHN risk varied by definition
of PHN (P 5 0.45), ascertainment of PHN (P 5 0.83),
immunosuppression status (P50.25), or sourcesof studypopulation
(P 5 0.97). These analyses were limited by 4/7 studies in meta-
analysis of gender having at least 1 bias domain assigned high-risk.
3.3.3. Severe immunosuppression
A cohort study among patients with zoster$18 years found
immunosuppression (including HIV, currently treated for cancer, or
exposed to high-dose corticosteroids) was more common in
patients with PHN (15%, n 5 3/20) than without (7.3%, n 5 6/82);
but the sample sizewas too small to be conclusive.27 Another cohort
study among patients $50 years of age reintroduced 12 patients
with immunosuppression excluded from the main analysis (defined
as using high-dose oral corticosteroids/other immunosuppressive
drugs, having invasive cancer or HIV/AIDS); these patients had an
increased risk of PHNafter adjustment for confounders (adjRR: 1.98,
95% CI: 1.14-3.45).13 Finally, the case-base study in the United
States found connective tissue disease, HIV, or organ allograft was
associated with 10-fold increased risk of PHN, although the CI was
wide (adjOR: 9.5, 95% CI: 2.0-45.0).8 Two studies specifically
assessed HIV: one excluded HIV from the final multivariable
analyses,38 whereas another found over 50% decreased risk of
PHN among patients with HIV (antiretroviral treatment status not
reported) (adjRR: 0.48, 95% CI: 0.26-0.86).23 The latter study also
reported strong evidence of an increased risk of PHN with
lymphoma/leukaemia (adjRR: 1.74, 95% CI: 1.32-2.28).
3.3.4. Other physical comorbidities
3.3.4.1. Overall physical health
One study measured overall health status at zoster presentation
using the physical component summary score and found
a decreased risk of PHN with better physical health.5 The second
study summed total number of reported medical conditions and
found no evidence of association with PHN.27
3.3.4.2. Autoimmune conditions
A large cohort study among 34,280 patients with zoster identified
in Taiwanese electronic health insurance records identified 284
patients with systemic lupus erythematosus (0.83%), who were
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Table 2
Association betweenPHNand various risk factors (defined as either vaccine-targetable or clinical features of the acute zoster episode): risk factors, adjusted effectmeasure and
95% confidence interval (CI) by study.
Vaccine-targetable risk factors Clinical features of the acute zoster episode
Age and gender Severe immune
suppression
Other physical or
psychological
comorbidities
Other risk factors Pain (including prodrome) Rash extent and
location
Rash duration Other
Cohort studies—risk
factor: OR (95% CI)
unless specified
Asada et al.2 50 s: 1.20 (0.33-4.44) — — Current smoker: OR not given — — — —
60 s: 0.73 (0.19-2.79) History of zoster: 0.42 (0.09-
1.88)
70 s: 1.72 (0.57-5.14) Diameter of red skin after VZV
skin test ($5 vs ,5 mm):
0.08 (0.02-0.45)
Reference $80 y Oedema after VZV skin test:
0.07 (0.01-0.62)
F vs M: 0.48 (0.22-
1.05)
Bouhassira et al.5 $70 vs ,70 y — Physical health, using
continuous PCS score,
* per 1 unit increase
(higher score5 worse
health): 0.72 (0.55-
0.92)
Family situation or living
arrangements not selected
for final model
Interference of pain on daily
tasks, using continuous ZBPI
score:1.18 (1.05-1.31)
— Delay in diagnosis not
selected for final model
Analgesic treatment
not selected for final
model
1.28 (1.05-1.55) Mental Health, using
continuous MCS score,
* per one unit increase
(higher score5 worse
health): P 5 0.59
Neuropathic pain score at
zoster presentation, using DN4
$4 vs ,4: 1.78 (1.03-3.06)
F vs M Associated disease
(undefined), anxiety or
depression not
selected for final model
Intensity tactile allodynia, using
continuous NPSI score: P 5
0.43
0.55 (0.34-0.90) Average pain intensity, using
continuous score from 1-10
using ZBPI: P 5 0.54
Pressure allodynia, brush-
evoked allodynia not selected
for final model
Cebria´n-Cuenca et al.†6 Per year increase:
1.04 (1.01-1.08,
P , 0.03)
— Other comorbidities
(Unclear if in final
model)
— Prodromic pain (OR not
reported: P . 0.05)
Zoster location (OR not
reported: P . 0.05)
Time from symptom onset
to diagnosis, time from
appearance of eruption to
diagnosis (OR not reported:
P . 0.05)
Antiviral use: OR not
given P . 0.05
Gender: OR not given
P . 0.05
(continued on next page)
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Table 2 (continued)
Vaccine-targetable risk factors Clinical features of the acute zoster episode
Age and gender Severe immune
suppression
Other physical or
psychological
comorbidities
Other risk factors Pain (including prodrome) Rash extent and
location
Rash duration Other
Coen et al.9 Age greater than 50 y:
3.91 (1.38-11.11)
— — — VAS .5: 3.92 (1.33-11.5) Extent of rash, score 1-
5: 1 (least rash,
baseline)
Time from onset of rash
(days): 0·93 (0.80-1.07)
—
F vs M: 2.45 (0.96-
6.23)
Prodrome not selected for final
model
2: 1.01 (0.18-5.61)
3: 1.65 (0.31-8.80)
4: 1.08 (0.15-7.59)
5: 2.52 (0.45-14.0)
Ophthalmic
involvement: 3.20
(1.19-8.55)
Drolet et al.12 Per yr increase: RR:
1.02 (1.00-1.04)
Immunosuppression
(using high-dose oral
corticosteroids or other
immunosuppressive
drugs, having invasive
cancer or HIV/AIDS):
RR: 1.98 (1.14-3.45)
(sensitivity analysis)
Limitation in
performing usual
activities before zoster:
RR: 1.66 (0.99-2.79)
Income, baseline $50,000
USD: $40K-49,999: RR: 2.24
(0.98-5.13)
Severe acute pain at zoster: RR:
2.06 (0.98-4.35)
Number of lesions
dermatome affected
not selected for final
model
Delay between recruitment
and rash onset not selected
for final model
Antiviral treatment,
timing of antiviral
treatment and other
medications not
selected for final
model
Gender not selected
for final model
Having another pain
condition or other pre-
zoster EQ-5D
measures not selected
for final model
$20K-39,999: RR: 1.77
(0.87-3.63)
Prodrome and its duration
reported, plus pain interference
score not selected for final
model
,$20K: 1.85 (0.89-3.83)
Working status or education
not selected for final model
Hannpaa et al.19 Per year increase:
1.06 (1.00-1.09)
— — — Moderate/severe acute pain:
OR not reported (no association
in univariate analysis)
Severity and
localization of rash:
ORs not reported
(neither associated in
univariate analysis)
— Pinprick hypesthesia:
7.72 (2.00-29.90)
Gender: OR not
reported (no
association in
univariate analysis)
Brush-evoked allodynia: 5.89
(1.50-23.1)
Antiviral use, analgesic
use not selected for
final model
Stretch-evoked allodynia: 4.13
(0.98-17.50)
Compression-allodynia: OR not
reported
Prodrome not selected for final
model
(continued on next page)
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Table 2 (continued)
Vaccine-targetable risk factors Clinical features of the acute zoster episode
Age and gender Severe immune
suppression
Other physical or
psychological
comorbidities
Other risk factors Pain (including prodrome) Rash extent and
location
Rash duration Other
Helgason et al.21 Per 10 y increase:
2.11 (1.56-2.84)
— — — — — — —
Gender not selected
for final model
Jih et al.†23 #60 vs .60 y: RR:
2.34 (2.17-2.53)
Lymphoma/leukaemia:
RR: 1.74 (1.32-2.28)
Diabetes: RR: 1.35
(1.25-1.47)
— — — — —
F vs M: RR: 0.95
(0.89-1.03)
HIV/AIDs: RR: 0.48
(0.26-0.86)
Breast cancer: RR0:
0.75 (0.53-1.06)
Liver cancer: RR: 0.86
(0.65-1.15)
SLE: RR: 2.27 (1.75-
2.94)
Jung et al.25 Per year increase:
1.03 (1.01-1.05)
— — — Presence of a prodrome: 2.75
(1.18-6.38)
Severe rash: 3.00
(1.88-4.81)
Rash duration, continuous
variable 0-24 h, 24-48 h,
48-72 h: 0.84 (0.64-1.11)
Clinical trial sample:
2.53 (1.61-3.99)
F vs M: 2.01 (1.28-
3.16)
Severe acute pain: 2.12 (1.35-
3.32)
Primary involvement of
the trigeminal
dermatome, number of
affected dermatomes,
presence of affected
nonadjacent
dermatomes not
selected for final
model
Kanbayashi et al.‡26 Per year increase in
age group (,50, 51-
74,$75): 2.74 (1.10-
6.76)
— Diabetes: 3.08 (0.79-
11.95)
— Prodromal pain: 1.55 (0.55-
4.41)
Localization not
selected for final
model
Period of onset (in days) not
selected for final model
—
Gender not selected
for final model
Sleep disorder: 1.16
(0.42-3.17)
Allodynia: 0.82 (0.24-2.81)
Hypertension, angina,
autoimmune
disorders, malignant
tumour not selected for
final model
Pain reduced by bathing: 3.39
(0.79-14.60)
Deep pain: 4.24 (1.11-16.16)
Breakthrough pain: 1.99 (0.62-
6.42)
(continued on next page)
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Table 2 (continued)
Vaccine-targetable risk factors Clinical features of the acute zoster episode
Age and gender Severe immune
suppression
Other physical or
psychological
comorbidities
Other risk factors Pain (including prodrome) Rash extent and
location
Rash duration Other
Katz et al.27 Per y increase: 1.07
(1.01-1.12)
Immunosuppression
(undefined, however,
included HIV, currently
being treated for
cancer or high-dose
corticosteroids): 1.59
(0.07-5.04)
Poorer physical health,
continuous variable
summing total number
of medical
conditions‡: 1.11
(0.93-1.32)
Race, education, marital
status not selected for final
model
Prodrome: 2.21 (0.54-9.15) Localization not
selected for final
model
Zoster duration, per day:
0.97 (0.88-1.07)
—
Gender not selected
for final model
Personality disorder
symptoms, per
symptom increase:
1.09 (1.01-1.18)
Zoster interferes with role
functioning: 2.34 (1.34-4.08)
Health locus of control,
disease conviction,
hypochondriasis,
premorbid physical,
role, and social
functioning before
zoster onset,
depression, and
anxiety symptoms not
selected for final model
Acute pain intensity, 0-10
composite score§ continuous
variable: 0.95 (0.69-1.32)
Somatosensory amplification
and somatic symptoms not
selected for final model
Kotani et al.28 Per 10 y increase: 2.2
(1.1-4.5)
— Diabetes, malignancy,
or autoimmune
disease not selected
for final model
— Prodrome: OR not reported Localization not
selected for final
model
— Cerebrospinal fluid
interleukin 8
concentrations at
healing of herpetic
rash (per 20-mg/L
increase: 1.8 (1.4-2.3)
Gender not selected
for final model
Acute pain: OR not reported Severity of skin rash:
OR not reported
Opstelten et al.33 #54: 1.00 — Diabetes: 1.7 (0.5-6.2) Consultation frequency not
selected for final model
Painful prodrome: 1.2 (0.3-5.6) Localization,
ophthalmic vs not: 2.2
(0.8-6.5)
— Chronic analgesics use
not selected for final
model
55-74: 5.4 (1.1-26.5) Psycho-
pharmaceuticals uses
1.4 (0.·3-5.6)
(continued on next page)
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Table 2 (continued)
Vaccine-targetable risk factors Clinical features of the acute zoster episode
Age and gender Severe immune
suppression
Other physical or
psychological
comorbidities
Other risk factors Pain (including prodrome) Rash extent and
location
Rash duration Other
$75: 19.7 (4.3-90.9) Chronic obstructive
pulmonary disease,
rheumatoid arthritis,
SLE, psychological
problem or
corticosteroid use at
zoster diagnosis not
selected for final model
F vs M: 1.0 (0.9-1.0)
Opstelten35 Per y: 1.08 (1.04-
1.12)
— Trust in health care
score, 1 unit increase
from 0-100 (higher
score relates to lower
trust): 1.01 (1.00-
1.03)
— Severity of acute pain, per VAS
unit: 1.02 (1.01-1.03)
Severe rash, $43
vesicles: 2.31 (1.16-
4.58)
Duration of rash before
consultation, in days: 0.78
(0.64-0.97)
Use of antivirals, VZV
antibodies (IgM, IgA,
IgG), VZV viremia not
selected for final
model
Gender not selected
for final model
Psychological
predictors including
anxiety disposition not
selected for final model
Park et al.37 $60 vs ,60 y: 8.50
(1.17-61.60)
— — — VAS for pain, $5 vs ,5: 4.78
(0.78-29.33)
Localization not
selected for final
model
Onset of rash,.3 d vs#3
d: 0.53 (0.08-3.28)
Temperature
differences between
normal and affected
skin: ,0.5˚C
(baseline)
F vs M: 0.73 (0.13-
4.24)
0.5˚C-1.0˚C: 8.25
(1.06-64.40)
.1.0˚C: 30.26 (1.68-
544.06)
% body surface area
with thermal
asymmetry2, $3 vs
,3%: 8.25 (0.24-
12.38)
Parruti et al.38 Per 10 y increase:
1.01 (0.99-1.02)
HIV not selected for
final model
Trauma at site of
lesion:2.53 (1.37-
4.65)
Current/former smoking:
2.08 (1.22-3.55)
Intense/very intense pain at
presentation: 2.19 (1.32-3.65)
Site of lesions and
severity of rash not
selected for final
model
— Antiviral use and
NSAIDs not selected
for final model
F vs M: 1.39 (0.84-
2.30)
Surgical intervention at
site of lesion: 1.33
(0.79-2.25)
Alcohol abuse, familial
status, educational level not
selected for final model
(continued on next page)
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Table 2 (continued)
Vaccine-targetable risk factors Clinical features of the acute zoster episode
Age and gender Severe immune
suppression
Other physical or
psychological
comorbidities
Other risk factors Pain (including prodrome) Rash extent and
location
Rash duration Other
HCV infection,
hypertension,
diabetes, neoplasm,
neurological disorders,
psychiatric illness,
allergy, or family
history of major
cardiovascular events,
malignancies,
neurological diseases,
major depression not
selected for final model
Volpi et al.46 .50 y vs #50: 2.58
(1.33-4.98)
— — Years of education not
selected for final model
Duration of prodromal pain (#3
vs .3 d): 0.49 (0.24-0.99)
Extent of rash: (.1 vs
1 dermatome): 2.27
(1.16-4.55)
— Antiviral therapy: 0.51
(0.10-2.50)
Gender not selected
for final model
Intensity of pain using the Short
Italian questionnaire, from 0-10
continuous variable: 1.17
(1.02-1.34)
Localization of rash not
selected for final
model
Abnormal sensations:
1.11 (1.02-1.34)
Presence of prodromal pain not
selected for final model
Wozniak et al.50 — — — APOE-e3: 4.98 (1·88-13.23) — — —
APOE-e4:0.25 (0.09-0.7)
(females only—no effect
among males)
Case-base studies—risk
factor: prevalence ratio
(95% CI)
Choo et al.‖,8 Per y: 1.12 (1.06-
1.18)
Connective tissue
disease, HIV infection
or organ allograft: 9.5
(2.0-45.9)
Diabetes: 2.7 (0.4-
17.·9)
Number of encounters
previous 180 d: 0-2
(reference)
Prodromal symptoms: 3.4
(1.3-9.1)
Thoracic (reference),
Cranial nerve V: 1.7
(0.3-9.3), Cervical: 1.1
(0.3-4.5), Lumbar/
sacral: 0.6 (0.2-2.0)
— Acyclovir exposure
after rash onset, days
(baseline is no
exposure): 0-3: 1.0
(0.4-2.6)
F vs M: 0.9 (0·4-2.3) Cancer: 0.1 (0.02-0.9) 3-4: 0.3 (0.1-0.9) Interference of pain on activities
on daily living: 1.3 (0.4-4.2)
Complications
(baseline is none):
Superinfection: 1.9
(0.5-7.6), Ocular: 2.1
(0.7-6.3), Oticus/TIA
from vasculitis/motor
neuropathy: 0.6
(0.2-2.0)
4-30: 1.0 (0.3-4.0)
(continued on next page)
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more than twice as likely to develop PHN (adjRR: 2.27, 95% CI:
1.75-2.94).23 Another smaller study (N 5 837) using electronic
medical records from the Netherlands collected data on lupus
and rheumatoid arthritis; however, they were not included in the
final model (numbers not reported).33
3.3.4.3. Diabetes
Three cohort studies reported point estimates for the association
between diabetes and PHN $1 in multivariable analyses;
however, there was insufficient evidence to confirm an associ-
ation.8,26,33 A larger cohort study among 34,280 patients with
zoster did find evidence of an increased risk (adjRR: 1.35, 95%CI:
1.25-1.47).23 There was no evidence of between-study hetero-
geneity for studies reporting age-adjusted diabetes effects
(Pheterogeneity 5 0.564; I
2 5 0.0%); the pooled effect estimate
was 1.36 (95% CI: 1.25-1.47) in the fixed effect meta-analysis;
however, the large study (N 5 34,280) dominated the pooled
relative risk (contributing 99.1% to the model).
3.3.4.4. Cancer
Five studies investigated cancer and its relationship with PHN; 3
excluded it from the final model.26,28,38 Breast and liver cancer were
investigated in a single study, but were not associated with PHN in
the final adjusted model.23 The case-base study found 13.5% of
PHN cases and 4.7% of non-PHN controls had a cancer diagnosis
180 days before zoster8; after adjustment, cancer was associated
with a reduced risk of PHN (adjOR: 0.1, 95%CI: 0.02-0.9); however,
the CIs were wide. A meta-analysis for cancer effect estimates was
not conducted as they involved different cancer sites.
3.3.4.5. Recent physical trauma
The only study to investigate this risk factor reported over 2-fold
increased risk of PHN associated with experiencing trauma at the
zoster site (contusions, burnings, wounds, and multiple traumas)
within 6 months before study enrolment.38
3.3.4.6. Other
Other physical conditions investigated aspredictors of PHN, but not
included in the age-adjusted models included surgical interven-
tion,38 hepatitis-C virus infection,38 hypertension,26,38 neurological
disorders,38 allergy,38 family history of coronary heart disease,38
angina,26 and chronic obstructive pulmonary disorder.33
3.3.5. Psychological comorbidities
These were assessed as risk factors for PHN in 4 studies. Two
cohort studies assessed a range of psychological comorbidities;
only personality disorder symptoms (adjOR: 1.09, 95% CI: 1.01-
1.18),27 and lower levels of trust in health care (adjOR: 1.01, 95%
CI: 1.00-1.03)35 showed a small association with PHN in
multivariable analyses. Neither depression nor anxiety was
included in multivariable analyses.5,27,35,38
3.3.6. Other risk factors
A cohort study found alipoprotein E-e3 was more common and
alipoprotein E-e4 less common among female patients with
zoster and PHN, suggesting that this host genetic factor may
influence the risk of PHN.50 One study found evidence that
current/former smoking was associated with greater risk of PHN
(adjOR: 2.08, 95%CI: 1.22-3.55)38 whereas another included it in
their final model, but did not report the association.2 One study
suggested a low state of varicella zoster virus (VZV)-specific
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Figure 2. Summary of associations between postherpetic neuralgia and clinical features of acute zoster. 1Composite score ranges from 0-100 numerical pain
ratings andMcGill Pain Questionnaire Present Pain 2Intensity ratings of average andworst shingles pain. Intensity of pain using the Short Italian questionnaire, from
0-10. 3Temperature differences are between normal and affected skin. 4Percentage of body surface area thermal asymmetry ($3 vs ,3%). †Risk factors too
varied to combine inmeta-analyses. •Not included in summary RR (either because study has already contributed tometa-analysis, or exposure definition is not in-
keeping with other studies). *Studies reporting RR (rather thanOR) are not included inmeta-analysis. CI, confidence interval; DN4, Neuropathic pain questionnaire
with 4 questions; NPSI, Neuropathic pain symptom inventory score; OR, odds ratio; RR, rate ratio; SF-12, short-form 12; VAS, visual analogue scale ranging from
0 (non pain) to 100 (worst pain ever experienced); VZV, varicella zoster virus; ZBPI, Zoster brief pain inventory interference score.
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Figure 3. Summary of associations between postherpetic neuralgia and vaccine-targetable risk factors from identified studies. *Only 10/20 studies reported age such
that the effect estimate could be converted into 10-year increases. Of the remaining 10 studies; 8 reported an increased risk of PHN with greater age, 1 showed no
effect all, and 1 did not report an age-effect. **Studies reporting RRs rather than ORs not included in meta-analysis as RR can underestimate OR when outcome
becomes common. ***Effect estimate from study may be erroneous therefore the study is not included in the meta-analysis: Parruti 2010 CIs are too narrow, and
Opstelten 2002 confidence also too narrow. 1Using high-dose oral corticosteroids or other immunosuppressive drugs, having invasive cancer or HIV/AIDS.
2Undefined, however included HIV or currently being treated for cancer. 3Connective tissue disease, HIV infection or organ allograft. 4Better health: measured using
continuous physical component summary score (higher scorer score reflects worse health). 5Poorer health: measured using continuous variable of total number of
medical conditions. †Risk factors too varied to combine inmeta-analyses. ‡The large study by Jih et al. (N5 34,280) dominated the pooled relative risk contributing to
99·1%of themodel. Other risk factors investigated as predictors of PHN, but not included in the final model, included; surgical intervention, hepatitis-C virus infection,
hypertension, neurological disorders, allergy, family history of CHD, angina, chronic obstructive pulmonary disorder, education, alcohol abuse, familial status, years of
education and race. APOE, alipoprotien E; CI, confidence interval; OR, odds ratio; RA, rheumatoid arthritis; RR, rate ratio; SLE, systemic lupus erythematosus.
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cell-mediated immunity, evidenced from reduced response to
VZV skin-test, was associated with greater risk of PHN.2 Studies
investigating education,13,27,38,46 race,27 being married,5,27,38
being in work,13 consultation rate,8,33 or alcohol abuse38 did not
select these risk factors in their final model.
Nine of the 19 studies had 2 or more definitions of PHN. Briefly,
studies additionally defined PHN as pain at 16,8,13,21,33,35,38 (n5 7)
and 6 months9,21,28 (n5 3) after zoster onset; there were no major
differences in study findings using these alternative definitions,
except older age was a stronger risk factor for pain persisting 6
months, compared with 2 or 3 months, after zoster (Appendix
Table A3, available online as Supplemental Digital Content at
http://links.lww.com/PAIN/A132), indicating older age may be
a risk factor for long-term PHN.
3.4. Assessment of bias
Our assessment of bias found 8/19 studies with at least 1
prespecified domainwith a high risk of bias, 8 studieswith at least 1
domain of medium risk, and 3 studies with only low or unclear risk
of bias. Residual confounding by age was the most common
source of potential bias, affecting 7/19 studies requiring age-
adjustment (Table 3). Studies using electronic health care records
were at greatest risk of reporting bias; specifically ascertainment
bias, where outcome ascertainment relies on patients returning to
their GP and higher general practice (GP) attendance could have
increased the chance of PHN diagnosis.8,23,26,33 Of the cohort
studies, 5 experienced loss to follow-up of greater than 10%
(Table 3). See Appendix Table A4 for detailed note on the bias
assessment (available online as Supplemental Digital Content at
http://links.lww.com/PAIN/A132).
The funnel plot gave a relatively symmetric pattern, suggesting
that there was little indication of publication bias (Fig. 4). The
distribution did not suggest that more extreme findings were
being selectively published.
The sampling methods and patient characteristics of some
studies suggest their external validitymay be limited; characteristics
of included patients indicate a nonrepresentative sample in some
studies (Coen et al. reported that 20% of the study population was
immunosuppressed8 and in 3 studies over 30% of the cohort
developed PHN28,46,50); 1 study used convenience sampling,6 thus
not all population members had an equal probability of being
selected; and the number or characteristics of eligible patients
refusing to participate were unclear in most studies.
4. Discussion
4.1. Summary of evidence
Our systematic review identified 19 prospective studies in-
vestigating risk factors for PHN. There was good evidence that
clinical features of acute zoster including prodromal pain, severe
Table 3
Assessment of bias for individual studies ( ).
Type of bias Confounding Selection bias Exposure information bias Outcome (PHN) information bias Bias due to missing
data
Residual confounding by
age
Loss to follow-
up
Nondifferential
misclassification
Reporting
bias
Nondifferential
misclassification
Missing exposure
data
Asada et al.2 ? ¤
Bouhassira et al.5 ¤ n ? ?
Cebria´n-Cuenca
et al.6
n ?
Coen et al.9 ¤ ? ? ?
Drolet et al.12 ? n
Haanpaa et al.19 n n ? ?
Helgason et al.21 ?
Jih et al.23 ¤ ? ? ¤ ¤ ?
Jung et al.25 n ?
Kanbayashi et al.26 ¤ ¤ ? ¤
Katz et al.27 n n ?
Kotani et al.28 ? ? ? ?
Opstelten et al.33 ¤ ¤ ¤ n
Opstelten35 ? n
Park et al.37 ¤ ? ? ? ?
Parruti et al.38 ? n
Volpi et al.46 ¤ ¤ ? n
Wozniak et al.50 ? ? ?
Choo, 19978 n n n
PHN, Postherpetic neuralgia.
0.00
0.20
0.40
0.60
0.80
1.00
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Figure 4. Assessment of publication bias for gender as a risk factor for
postherpetic neuralgia. Funnel plot of the log odds ratio plotted against the
standard error of the log odds ratio for seven studies reporting the effect of female
gender on PHN risk (dotted line represents pseudo 95% confidence limits).
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acute pain, severe rash, and ophthalmic involvement were
associated with increased risk of PHN. Rash duration at zoster
presentation was less strongly associated with PHN. Regarding
vaccine-targetable risk factors, older age was consistently
associated with PHN. The evidence for gender as a risk factor
was conflicting. Immunosuppression and diabetes were signifi-
cantly associated with PHN in a few, but not all studies. Systemic
lupus erythematosus, recent trauma, and personality disorder
symptoms were associated with PHN; however, evidence came
from single studies only. No studies found evidence suggesting
that depression or cancer was associated with increased risk of
PHN. Most studies had small sample sizes reducing their power
to detect associations. Our review highlights that we have a good
understanding of which clinical features of zoster predict PHN,
yet there is a need for better evidence on common and potentially
easily vaccine-targetable risk factors for PHN prevention.
4.2. Interpreting the findings
It is believed that several pathophysiological mechanisms may
contribute to the development of PHN. Acute zoster infection
undoubtedly results in nerve damage to both the peripheral and
central nervous system, yet the nature of the damage and specific
mechanism resulting in persistent pain are not fully understood.4
There are 2 (nonmutually exclusive) hypotheses for its development;
the first is that persistence of VZV after acute zoster, at higher levels
than during latency, causes continued pain; and the second, that
after acute zoster infection, there is increased neuronal excitability
and alteration of pain perception caused by neural damage.1,20
The variety of possible risk factors for PHN identified in the review
may reflect these different mechanisms.3 The finding that greater
rash severity and greater acute pain are associated with increased
risk of PHN supports the notion that greater neural damage caused
bymore severe infection contributes to the development of PHN.15
That longer rash durationwas associatedwith reduced risk of PHN
initially seems inconsistent with the finding that more severe zoster
rash is associated with PHN. However, late presentation might
indicate patients had milder zoster not immediately demanding
medical attention. Either way, this finding is unlikely to be due to the
duration of the rash itself. Patients with ophthalmic zoster seem at
greater risk of PHN, although it is not clear whether concerns about
eye complications cause them to react differently, rather than the
increased risk being driven by a biological mechanism.20 Ageing
undoubtedly causes a waning of cell-mediated immunity and may
cause increased levels of the virus after zoster reactivation,
potentially causing PHN. Other risk factors for PHN identified here
are also associated with reduced cell-mediated immunity, in-
cluding severe immunosuppression, systemic lupus erythemato-
sus, and smoking. Trauma at the site of the rash may induce local
changes facilitating reactivation of herpes zoster (HZ) and greater
nerve damage leading to increased risk of PHN. However, the
aetiological mechanism(s) by which these risk factors affect the
development of PHN remains largely unknown.
4.3. Limitations of the selected studies
The included studies had some limitations. Many had small
sample sizes, and we were unable to combine some results in
a meta-analysis. Furthermore, many tested a number of risk
factors; the associations observed may occur by chance due to
testing multiple exposures. Most studies based zoster diagnosis
on clinical opinion rather than serological or virological testing; this
may have led tomisclassification of patients with zoster; however,
clinical diagnosis is typically reliable.34
Some studies may have been affected by specific biases. Age is
a very strong predictor of PHN and yet 7/18 studies assessing age
adjusted for it as a binary or categorical variable with wide age
intervals, potentially causing residual confounding by age. Loss to
follow-up affected 5/19 studies, and if loss to follow-up is
associated with both PHN and the risk factor, bias could have
been introduced.18 Patients with PHNmay be more likely to return
for follow-up as they require continued care, and patients with
particular risk factors may also return to their GP more commonly,
making bias due to loss to follow-up likely. Ascertainment biasmay
have affected studies using routinely collected health care data.
Here, spurious associations between PHN andmedical conditions
requiring regular contact with health care professionals may arise.
One such study adjusted for health care utilisation8 and still found
a positive association with PHN and certain immunosuppressive
disorders, suggesting the effect cannot be driven solely by
ascertainment bias. Finally, not all studies adjusted for clinical
features of the acute zoster episode,2,21,23 and results may be
subject to residual confounding.
4.4. Strengths and limitations of the review
This is the first study to systematically review the literature on risk
factors for PHN; although clinical features of acute zoster have
been acknowledged as risk factors for PHN, this is the first to
summarise age-adjusted results and pool them in a meta-
analysis. We undertook a comprehensive search of several
databases using multiple keywords and indexed subject head-
ings. The reliability of study selection criteria was confirmed by
double screening of 10% of the articles.
There are some important limitations to this review. There is no
consensus over the exact definition of PHN; in this review, PHN
definitions ranged frompainpersisting1 to6months after rashonset,
with some studies assessing any pain, whereas others required
severe pain. A full assessment of risk factors by different PHN
classifications was not possible here because of too few studies.
Between-study variability prevented us frompooling the effects
of age and gender on PHN; there was some evidence that age of
the study population contributed to the observed heterogeneity.
However, these analyses were limited by the small number of
studies and may have reduced our power to detect associations.
Variability may be due to different adjustment for confounders or
some studies reporting biased effect estimates, eg, due to PHN
measurement error or loss to follow-up. Studies also used
different definitions for certain clinical features of acute zoster,
such as severe acute pain and severe rash, potentially giving
some heterogeneity to the results.
Our search strategy may have missed some studies; however,
we used multiple databases (including grey literature) and
searched reference lists of selected articles, to minimise this
issue. As with any literature review, studies finding no effects may
have gone unpublished. Our funnel plot did not demonstrate any
evidence of publication bias with respect to assessing gender as
a risk factor for PHN. However, publication bias may affect other
risk factors differently, and there were not enough studies per risk
factor to assess this for other exposures. Finally, non–English-
language articles were excluded because of resource limitations;
however, the authors believe it is unlikely to have led to the
omission of any major articles in the area.
4.5. Implications
Zoster vaccination offers a way of preventing this debilitating
complication by preventing zoster itself, but is currently
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expensive; therefore, targeting the vaccine toward groups at
high-risk of PHN may be beneficial. The vaccine is currently
licensed in certain countries in the European Union, United
States, and Australia.49 It is targeted at older age groups and
contraindicated in patients with severe immunosuppression. As
older age is the only indisputable risk factor that vaccination
policies can use, this approach seems reasonable. If patients with
severe immunosuppression are at increased risk of PHN as
suggested by this review, in addition to being at greater risk of
zoster itself, there is even more need to identify alternative
strategies to prevent zoster in these groups.
This review has highlighted our lack of understanding of
vaccine-targetable risk factors for PHN, and the need to perform
studies exploring suggested associations. Such studies would
need to be generalizable to a wide group, by recruiting patients
aged 18 and over and including immunosuppressed patients, to
examine the risk of PHN by age and immunosuppression status.
Other desirable features would include recruiting a large number
of individuals to achieve greater power to help detect small
effects, collecting data on all known and possible risk factors for
PHN, actively following up patients with zoster to allow persistent
pain to be identified for the entire cohort at the same time and
reducing loss to follow-up to avoid differential ascertainment of
PHN. Finally, at the analysis stage, detailed adjustment for age
using either a continuous or finely categorised age variable would
reduce residual confounding by age.
5. Conclusions
This study confirms that features of the acute zoster episode,
including prodromal pain, severe rash, severe acute pain, and
ophthalmic involvement are risk factors for PHN. Our current
understanding of vaccine-targetable risk factors for PHN is
however limited. There are some suggestions that immunosup-
pression, systemic lupus erythematosus, diabetes, and recent
trauma may be associated with greater risk of PHN. Increasing
age is the only established risk factor for PHN that has been
quantified with sufficient rigour as to usefully inform vaccine
policy. Larger studies with greater power to detect associations,
and studies addressing the limitations of previous research, may
elucidate some of the unknown risk factors for PHN.
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